IJASRM

International Journal of Advanced Scientific Research and Management, Volume 10 Issue 03, Mar 2025

www.ijasrm.com

ISSN 2455-6378

Beyond Gut Dysbiosis: Gut Microbiome-Based Precision Nutrition for Reversing Insulin Resistance—Mechanisms, Clinical Evidence, and Future Perspectives

Monika Chauhan[1]

[1] Ex-Associate Professor, Department of Chemical Engineering, Adama Science and Technology University, Adama, Ethiopia

Abstract

Background: Insulin resistance (IR) is the pathophysiological core of type 2 diabetes and metabolic syndrome, and conventional dietary advice—built on population-averaged macronutrient targets—has yielded inconsistent results at the individual level. The gut microbiome has emerged as a modifiable node linking diet to host metabolism, yet most reviews still frame it narrowly around compositional "dysbiosis."

Objective: This review moves beyond dysbiosis to synthesize how gut microbial function, microbial metabolites, and host molecular signaling converge to shape insulin sensitivity, and to outline how this mechanistic knowledge can be translated into precision nutrition.

Key evidence: Landmark metagenome-wide association studies and interventional fiber trials demonstrate that reduced microbial gene richness, depletion of short-chain fatty acid (SCFA)-producing taxa, and altered bile acid and branched-chain amino acid (BCAA) metabolism causally contribute to insulin resistance, while diet-responsive taxa such as Akkermansia muciniphila and Faecalibacterium prausnitzii track with improved metabolic outcomes.

Major findings: Microbial functional capacity—not composition alone—determines host metabolic response to diet; fiber type, fermented foods, polyphenols, and synbiotic combinations produce individually variable glycemic responses that can be partly predicted from baseline microbiome and metabolome features.

Research gaps: Standardized functional metrics, causal validation beyond association, underrepresentation of South Asian and other non-Western populations, and a lack of validated predictive algorithms remain unresolved.

Future perspectives: Integration of metagenomics, metabolomics, nutrigenomics, and artificial intelligence into a unified, clinically deployable framework offers the most plausible route from mechanistic insight to individualized dietary prescriptions capable of reversing—not merely managing—insulin resistance.

Keywords: *gut microbiome; insulin resistance; precision nutrition; short-chain fatty acids; metabolomics; artificial intelligence; type 2 diabetes*

1. Introduction

Insulin resistance (IR) is the central pathophysiological defect underlying type 2 diabetes mellitus (T2DM), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and several cardiometabolic disorders, affecting hundreds of millions of individuals worldwide [1–4]. The prevalence of insulin resistance continues to rise due to urbanization, sedentary lifestyles, unhealthy dietary habits, obesity, and population aging, creating an enormous clinical and economic burden on healthcare systems worldwide [1,2].

Conventional dietary management of insulin resistance has primarily focused on generalized recommendations such as reducing refined carbohydrates, limiting saturated fats, increasing dietary fiber intake, and promoting weight loss [5]. Although these recommendations improve metabolic health at the population level, considerable inter-individual variability exists in glycemic responses to identical meals, suggesting that uniform dietary advice is insufficient for optimal metabolic control [6].

Precision nutrition has therefore emerged as a novel paradigm that integrates individual genetic, metabolic, environmental, and microbial characteristics to develop personalized dietary interventions [6,7]. Among these determinants, the gut microbiome has

https://doi.org/10.36282/IJASRM/10.03.2025.1961

IJASRM

www.ijasrm.com

ISSN 2455-6378

attracted particular attention because it directly mediates interactions between diet and host metabolism through production of numerous bioactive metabolites [8–10].

The human gastrointestinal tract harbors trillions of microorganisms whose collective genome contains substantially more genes than the human genome itself [8]. These microorganisms participate in digestion of complex carbohydrates, synthesis of vitamins, metabolism of bile acids, production of short-chain fatty acids (SCFAs), regulation of immune homeostasis, maintenance of intestinal barrier integrity, and modulation of host energy metabolism [8–11].

Numerous metagenomic investigations have demonstrated that alterations in gut microbial composition and function are associated with obesity, insulin resistance, and type 2 diabetes [1,12–15]. However, recent evidence suggests that microbial functional capacity rather than microbial composition alone is a stronger determinant of metabolic health [9,16]. Individuals possessing distinct microbial communities may nevertheless generate similar metabolic outputs, whereas taxonomically similar communities may exhibit markedly different metabolic activities because of strain-level genetic differences and dietary substrate availability [16–18].

Accordingly, the emphasis of microbiome research is shifting from descriptive analyses of microbial composition toward functional characterization of microbial metabolism and host-microbe interactions. This review therefore synthesizes current evidence linking gut microbial ecology, microbial metabolites, host molecular signaling pathways, and precision nutrition strategies for reversing insulin resistance while proposing an AI-integrated conceptual framework for future clinical translation.

Increasing evidence indicates that gut dysbiosis contributes to insulin resistance through multiple interconnected mechanisms, including increased intestinal permeability, altered microbial metabolite production, bile acid dysregulation, branched-chain amino acid metabolism, and chronic low-grade inflammation. These mechanisms collectively impair insulin signalling in metabolically active tissues and provide the biological basis for microbiome-targeted nutritional interventions.




Figure 1. Gut Microbiome–Host Crosstalk in Insulin Resistance. Gut dysbiosis affects intestinal permeability, microbial metabolite production, and systemic inflammation, collectively impairing insulin signaling.

The molecular pathways linking these microbial alterations with host insulin signalling are discussed in the following section.

2. Beyond Gut Dysbiosis: Microbial Ecology in Insulin Resistance

https://doi.org/10.36282/IJASRM/10.03.2025.1961

A metabolically healthy gut microbiome is characterized less by any single "ideal" composition than by high microbial gene richness, functional redundancy, and resilience—the capacity to maintain core metabolic outputs (SCFA production, bile acid transformation, mucin turnover) despite everyday dietary fluctuation. This functional stability, rather than a fixed taxonomic blueprint, is what appears to protect against metabolic disease.

Gut microbial metabolites regulate host metabolism through several interconnected signalling pathways, including AMPK, PI3K–Akt, GLP-1, FXR/TGR5, mTOR, and NF-κB. These pathways influence glucose homeostasis, insulin sensitivity, inflammatory responses, and mitochondrial function.




Figure 2. Precision Nutrition Strategy for Improving Insulin Resistance Through Gut Microbiome Modulation.

Landmark metagenomic and interventional studies have established the empirical basis for the mechanistic links discussed throughout this review; the most influential of these are summarized in Table 1.

Table 1. Landmark Studies on Gut Microbiome and Insulin Resistance

Study (indicative)	Design	Key Contribution
Qin et al., 2012	Metagenome-wide association	First large-scale metagenomic evidence linking gut microbial gene signatures to T2DM
Le Chatelier et al., 2013	Cross-sectional metagenomic	Low microbial gene richness associated with adiposity, IR, and inflammation
Karlsson et al., 2013	Case-control metagenomic	Distinct microbial gene clusters associated with T2DM in European women
Ridaura et al., 2013	Gnotobiotic transplantation	Causal transfer of obesity/metabolism phenotypes via microbiota
Zeevi et al., 2015	Prospective + ML modeling	ML prediction of individualized postprandial glycemic response
Pedersen et al., 2016	Cross-sectional metabolomic	Gut microbiota-linked serum BCAAs associated with IR
Zhao et al., 2018	Randomized fiber intervention	Diverse dietary fiber promotes SCFA producers and improves glycemic control

Dysbiosis in the context of insulin resistance is typically described as a shift toward reduced overall microbial diversity, expansion of pro-inflammatory or mucin-degrading taxa, and contraction of taxa associated with SCFA production and gut barrier

https://doi.org/10.36282/IJASRM/10.03.2025.1961

maintenance. Individuals with low microbial gene richness consistently show a more adverse metabolic profile than individuals with high richness, even at similar body weight.

Several keystone taxa recur across studies. Akkermansia muciniphila reinforces gut barrier integrity and is depleted in IR. Faecalibacterium prausnitzii and Roseburia are major butyrate producers. Bifidobacterium supports SCFA production and barrier function. Principal taxa are summarized in Table 2.

Table 2. Beneficial and Harmful Gut Microbial Taxa Associated with Insulin Resistance

Taxon	Association	Proposed Mechanism
Akkermansia muciniphila	Beneficial (depleted in IR)	Mucin turnover, barrier reinforcement, reduced endotoxemia
Faecalibacterium prausnitzii	Beneficial (depleted in IR)	Major butyrate producer, anti-inflammatory
Roseburia spp.	Beneficial (depleted in IR)	Butyrate production, SCFA-mediated AMPK activation
Bifidobacterium spp.	Beneficial (depleted in IR)	SCFA production, barrier support, probiotic anchor
Enterobacteriaceae (e.g. Escherichia)	Harmful (enriched in IR)	LPS source, pro-inflammatory endotoxemia
Desulfovibrio spp.	Harmful (enriched in IR)	H2S production, mucin layer degradation
Ruminococcus gnavus	Harmful (enriched in IR)	Mucin degradation, pro-inflammatory polysaccharides

The more consequential shift is from cataloguing taxa to characterizing functional capacity. Two individuals can harbor different taxonomic profiles yet converge on similar functional outputs. Clinical benefit tracks more closely with restoration of functional capacity—fermentative output, barrier-supportive metabolites, bile acid transformation—than with any particular taxonomic endpoint.

3. Molecular Mechanisms Linking Gut Microbiome to Insulin Resistance

3.1 Gut Barrier Dysfunction and Metabolic Endotoxemia

One of the earliest mechanistic links is disruption of intestinal barrier integrity [19]. Reduced microbial diversity and depletion of butyrate-producing bacteria impair mucus production and tight junction proteins (occludin, claudin, ZO-1), resulting in increased intestinal permeability [19–21]. Circulating LPS activates TLR4, leading to MyD88-dependent NF-κB activation, TNF-α and IL-6 production, and impaired insulin receptor signaling via serine phosphorylation of IRS-1 [19–23].

3.2 Short-Chain Fatty Acids

SCFAs (acetate, propionate, butyrate) are the principal beneficial metabolites from microbial fermentation of dietary fiber [24–27]. They activate FFAR2/FFAR3, stimulate GLP-1 and PYY, enhance mitochondrial β-oxidation via AMPK, suppress inflammation, and maintain epithelial barrier integrity [24–28]. Butyrate is the primary energy source for colonocytes and inhibits HDACs. Reduced Faecalibacterium prausnitzii and Roseburia are associated with obesity, IR, and T2DM [13,29].

3.3 Bile Acid Signaling

Gut microorganisms transform primary bile acids into secondary bile acids via bile salt hydrolase, regulating FXR and TGR5 signaling [30–32]. These receptors influence glucose metabolism, hepatic gluconeogenesis, lipid oxidation, energy expenditure, and GLP-1 secretion. Altered microbial composition disrupts bile acid homeostasis and contributes to impaired glucose regulation and systemic IR [31,32].

3.4 Branched-Chain Amino Acids

Elevated circulating BCAAs are strongly associated with IR [33–35]. Certain gut microbial communities preferentially synthesize BCAAs, which activate mTOR–S6K1 and promote inhibitory serine phosphorylation of IRS-1, impairing downstream insulin signaling [33–35].

3.5 Inflammatory Signaling

Metabolic endotoxemia, reduced SCFA production, altered bile acid metabolism, and microbial metabolites culminate in chronic activation of NF-κB, JNK, TNF-α, IL-6, and NLRP3 inflammasome signaling [22,23,36], contributing to IR in liver, skeletal muscle, and adipose tissue [36–38].

3.6 Gut–Brain, Gut–Liver and Gut–Muscle Axes

SCFAs regulate appetite via vagal signaling and hypothalamic neuropeptides (gut–brain axis) [39]. Portal transport influences hepatic lipid metabolism and gluconeogenesis (gut–liver axis) [40]. Microbial metabolites enhance skeletal muscle mitochondrial biogenesis, GLUT4 translocation, and insulin-mediated glucose uptake (gut–muscle axis) [41].

https://doi.org/10.36282/IJASRM/10.03.2025.1961

ISSN 2455-6378

4. Gut Microbiome-Based Precision Nutrition

Precision nutrition recognizes that identical foods produce different metabolic responses among individuals [6,42]. Machine-learning algorithms integrating dietary intake, microbiome, clinical characteristics, and biochemical markers substantially improve prediction of individualized postprandial glycemic responses [6].

Dietary fiber remains the most effective strategy for improving microbial function and insulin sensitivity [27,43]. Fermentable fibers increase diversity, stimulate SCFA producers, improve barrier function, and enhance insulin sensitivity [27,43–45]. Responses depend on fiber structure, solubility, chain length, and baseline microbiota [44].

Resistant starch promotes butyrate production [45]. Polyphenol-rich foods selectively enrich Akkermansia muciniphila [46–48]. Fermented foods improve diversity and reduce inflammation [49]. Personalized probiotics and synbiotics enhance colonization and SCFA production [50,51]. Postbiotics offer activity without viability challenges [52].

Table 3. Dietary Components, Gut Microbial Modulation, and Metabolic Outcomes

Dietary Component	Microbial Modulation	Metabolic Outcome
Diverse/complex dietary fiber	↑ SCFA-producing taxa, ↑ gene richness	Improved glycemic control, reduced HbA1c
Resistant starch	↑ butyrate producers	Improved insulin sensitivity
Fermented foods	↑ microbial diversity, ↓ inflammation	Reduced systemic inflammation
Polyphenols	↑ Akkermansia and related taxa	Improved barrier, reduced endotoxemia
Personalized probiotics	Strain-specific engraftment	Benefit contingent on host compatibility
Synbiotic combinations	Combined substrate + strain	More consistent benefit in early trials

Precision nutrition seeks to identify which dietary intervention is most effective for which individual, using microbiome profiling, metabolomics, nutrigenomics, and AI [6,7,42,53].

This integrated framework represents a paradigm shift from population-based dietary advice toward individualized nutritional therapy.

Table 4. Emerging Technologies in Precision Nutrition

Technology	Primary Application	Contribution
Shotgun metagenomics	Species/strain, functional genes	Functional capacity beyond taxonomy
Metabolomics	SCFAs, bile acids, BCAAs	Direct functional readout
Nutrigenomics	Host genetic nutrient response	Host-side personalization
Machine learning	Glycemic/metabolic prediction	Individualized response prediction
Deep learning	Multi-omics pattern recognition	High-dimensional interactions
Digital twins	Dynamic physiological modeling	In silico dietary simulation
Clinical decision support	Translation to practice	Clinician-facing actionable output

https://doi.org/10.36282/IJASRM/10.03.2025.1961




Figure 3. Workflow of Microbiome-Guided Precision Nutrition. Integrating dietary assessment, gut microbiome profiling, metabolomic analysis, artificial intelligence, personalized dietary intervention, and continuous metabolic monitoring.

https://doi.org/10.36282/IJASRM/10.03.2025.1961

ISSN 2455-6378

5. Emerging Technologies

Translation of gut microbiome science into clinical practice depends on technological advances in sequencing, metabolomics, AI, and systems biology [36–39].

5.1 Shotgun Metagenomics

Shotgun metagenomics provides species- and strain-level resolution and identifies functional genes [36,40], enabling reconstruction of pathways for SCFA biosynthesis, bile acid transformation, and amino acid metabolism [36,41]. Microbial gene richness is more strongly associated with insulin sensitivity than composition alone [13,40].

5.2 Metabolomics

Metabolomics quantifies microbial metabolites in plasma, urine, feces, and saliva via LC-MS, GC-MS, and NMR [42–44]. Metabolomic profiles often correlate more closely with metabolic phenotype than microbial abundance [43].

5.3 Nutrigenomics

Host genetic variation contributes to inter-individual dietary responses [45]. Combining nutrigenomics with microbiome analysis improves personalization of interventions for IR [46].

5.4 Artificial Intelligence and Machine Learning

AI integrates multi-omics datasets into clinically actionable recommendations [6,47]. ML predicts individualized postprandial glycemic responses more accurately than carbohydrate counting [6]. Deep learning captures nonlinear interactions among thousands of variables [47,48].

5.5 Multi-Omics Integration

Integration of genomics, transcriptomics, proteomics, metagenomics, metabolomics, and clinical phenotyping enhances predictive accuracy [49]. Network-based approaches identify key regulatory pathways [49,50].

5.6 Digital Twins and Clinical Decision Support

Digital twins simulate an individual's physiological, metabolic, and microbial characteristics [51]. Clinical decision support systems integrating microbiome, metabolomics, wearables, EHRs, and AI may enable real-time personalized recommendations [52].

5. Emerging Technologies

Translation of gut microbiome science into clinical practice depends on technological advances in sequencing, metabolomics, AI, and systems biology [36–39].

5.1 Shotgun Metagenomics

Shotgun metagenomics provides species- and strain-level resolution and identifies functional genes [36,40], enabling reconstruction of pathways for SCFA biosynthesis, bile acid transformation, and amino acid metabolism [36,41]. Microbial gene richness is more strongly associated with insulin sensitivity than composition alone [13,40].

5.2 Metabolomics

Metabolomics quantifies microbial metabolites in plasma, urine, feces, and saliva via LC-MS, GC-MS, and NMR [42–44]. Metabolomic profiles often correlate more closely with metabolic phenotype than microbial abundance [43].

5.3 Nutrigenomics

Host genetic variation contributes to inter-individual dietary responses [45]. Combining nutrigenomics with microbiome analysis improves personalization of interventions for IR [46].

5.4 Artificial Intelligence and Machine Learning

AI integrates multi-omics datasets into clinically actionable recommendations [6,47]. ML predicts individualized postprandial glycemic responses more accurately than carbohydrate counting [6]. Deep learning captures nonlinear interactions among thousands of variables [47,48].

5.5 Multi-Omics Integration

Integration of genomics, transcriptomics, proteomics, metagenomics, metabolomics, and clinical phenotyping enhances predictive accuracy [49]. Network-based approaches identify key regulatory pathways [49,50].

5.6 Digital Twins and Clinical Decision Support

Digital twins simulate an individual's physiological, metabolic, and microbial characteristics [51]. Clinical decision support systems integrating microbiome, metabolomics, wearables, EHRs, and AI may enable real-time personalized recommendations [52].

https://doi.org/10.36282/IJASRM/10.03.2025.1961

ISSN 2455-6378




Figure 4. Integration of AI and Multi-Omics Technologies into Personalized Nutrition

https://doi.org/10.36282/IJASRM/10.03.2025.1961

ISSN 2455-6378

6. Challenges, Gaps, and Future Perspectives

6.1 Scientific Challenges

Extraordinary inter-individual microbiome variability (genetics, ethnicity, geography, age, medications, diet, lifestyle) limits generalizability [53]. Most studies remain cross-sectional [54]. Methodological heterogeneity complicates comparison [55].

6.2 Clinical Challenges

High cost of shotgun metagenomics, metabolomics, and bioinformatics constrains routine implementation [56]. Standardized clinical guidelines and regulatory pathways remain under development [56,57].

6.3 Population Representation

Research has been dominated by North American and European cohorts; South Asian, African, Middle Eastern, and Latin American populations remain underrepresented [58]. Predictive algorithms from Western cohorts may have limited applicability elsewhere.

6.4 Future Perspectives

Future work should prioritize functional biomarkers over taxonomic signatures [40,59], integrate multi-omics with AI [47,49], advance microbial therapeutics [60], and conduct large prospective RCTs [54].

Table 5. Current Limitations, Knowledge Gaps, and Future Research Priorities

Domain	Current Limitation	Future Priority
Population representation	Western cohort overrepresentation	Study of underrepresented populations
Study design	Predominantly cross-sectional	Longitudinal causal intervention studies
Methodology	Inconsistent pipelines	Field-wide standardization
Validation	Limited multi-omics validation	Cross-cohort biomarker replication
Translation	Retrospective algorithms	Prospective dietary algorithm validation
Implementation	AI untested clinically	Real-world deployment tracking
Cost and access	Multi-omics remains costly	Scalable functional biomarkers

7. Conclusions

Insulin resistance is a multifactorial disorder in which the gut microbiome regulates barrier integrity, metabolite production, inflammatory signaling, bile acid metabolism, and inter-organ communication [19,24,30]. Microbial functional capacity rather than composition alone is the principal determinant of host metabolic responses [16,40].

Dietary fiber, resistant starch, fermented foods, polyphenols, probiotics, synbiotics, and postbiotics are promising approaches [27,46,50], but heterogeneity in response emphasizes personalization over universal guidelines.

Shotgun metagenomics, metabolomics, nutrigenomics, AI, and multi-omics integration are expected to transform microbiome research into clinically actionable strategies [36,47,49]. Challenges of standardization, causal validation, cost, regulation, and diverse populations must be addressed first.

Gut microbiome-based precision nutrition is one of the most promising frontiers in metabolic medicine for preventing, managing, and potentially reversing insulin resistance [6,47,60].

Key Take-Home Messages

- Functional microbial capacity is more informative than taxonomic composition.
- SCFAs remain central mediators of microbiome–host metabolic interactions.
- Precision nutrition should target microbial function rather than individual taxa.
- AI and multi-omics technologies are accelerating clinical translation.
- High-quality longitudinal randomized trials remain essential.

Limitations of the Review

This review focuses on human and translational evidence but is not a formal systematic review or meta-analysis. Rapidly evolving evidence may alter current understanding, particularly regarding microbial therapeutics and AI-assisted nutrition.

https://doi.org/10.36282/IJASRM/10.03.2025.1961


IJASRM

International Journal of Advanced Scientific Research and Management, Volume 10 Issue 03, Mar 2025

www.ijasrm.com

ISSN 2455-6378

Graphical Abstract



https://doi.org/10.36282/IJASRM/10.03.2025.1961

ISSN 2455-6378

References

1. DeFronzo RA. Banting Lecture 2008: From the triumvirate to the ominous octet. Diabetes. 2009;58(4):773–795.
2. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF; 2021.
3. American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1–S350.
4. Samuel VT, Shulman GI. Mechanisms for insulin resistance. Cell. 2016;148:852–871.
5. World Health Organization. Healthy Diet Fact Sheet. Geneva: WHO; 2023.
6. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163:1079–1094.
7. Ordovas JM, Ferguson LR, Tai ES, et al. Personalised nutrition and health. BMJ. 2018;361:k2173.
8. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369–2379.
9. Gilbert JA, Blaser MJ, Caporaso JG, et al. Current understanding of the human microbiome. Nat Med. 2018;24:392–400.
10. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361:k2179.
11. Flint HJ, Scott KP, Duncan SH, Louis P. Microbial degradation of complex carbohydrates. Gut Microbes. 2012;3:289–306.
12. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.
13. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–546.
14. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with type 2 diabetes. Nature. 2013;498:99–103.
15. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism. Science. 2013;341:1241214.
16. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med. 2016;8:51.
17. Turnbaugh PJ, et al. Functional interactions between diet and gut microbiota. Nature. 2009;457:480–484.
18. Zmora N, Suez J, Elinav E. Personalized microbiome interventions. Cell. 2019;177:1430–1443.
19. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–1772.
20. Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier function. Exp Mol Med. 2018;50:1–9.
21. Camilleri M. Leaky gut and intestinal permeability. Gut. 2019;68:1516–1526.
22. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867.
23. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98–107.
24. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: SCFAs. Cell. 2016;165:1332–1345.
25. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in metabolic health. Nat Rev Endocrinol. 2015;11:577–591.
26. Morrison DJ, Preston T. Formation of SCFAs by the gut microbiota. Gut Microbes. 2016;7:189–200.
27. Zhao L, Zhang F, Ding X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018;359:1151–1156.
28. Blaak EE, et al. SCFAs and human metabolic health. Nat Rev Endocrinol. 2020;16:693–716.
29. Louis P, Flint HJ. Diversity and metabolism of butyrate-producing bacteria. Nat Rev Gastroenterol Hepatol. 2017;14:577–589.
30. Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Bile acids and gut microbiota. Cell Metab. 2016;24:41–50.
31. Sun L, Cai J, Gonzalez FJ. FXR signaling in metabolic diseases. Signal Transduct Target Ther. 2021;6:172.
32. Li T, Chiang JYL. Bile acid signaling in metabolic regulation. Compr Physiol. 2014;4:1191–1212.
33. Pedersen HK, Gudmundsdottir V, Nielsen HB, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016;535:376–381.
34. Newgard CB, et al. Branched-chain amino acids and metabolic disease. Cell Metab. 2009;9:311–326.
35. Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling. Nat Rev Endocrinol. 2014;10:723–736.
36. Quince C, Walker AW, Simpson JT, Loman NJ, Segata N. Shotgun metagenomics, from sampling to analysis. Nat Biotechnol. 2017;35(9):833–844.
37. Knight R, Vrbanac A, Taylor BC, et al. Best practices for analysing microbiomes. Nat Rev Microbiol. 2018;16(7):410–422.
38. Integrative HMP Research Network Consortium. The Integrative Human Microbiome Project. Nature. 2019;569(7758):641–648.
39. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med. 2016;8:51.
40. Vieira-Silva S, Falony G, Belda E, et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature. 2020;581(7808):310–315.
41. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut microbiome structure and metabolic activity in IBD. Nat Microbiol. 2019;4(2):293–305.
42. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17(7):451–459.
43. Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev. 2019;99(4):1819–1875.
44. Nicholson JK, Holmes E, Kinross JM, et al. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262–1267.
45. Ferguson LR. Nutrigenomics approaches to functional foods. J Am Diet Assoc. 2009;109(3):452–458.
46. Corella D, Ordovás JM. Interactions between dietary components and genetic variants. Curr Opin Lipidol. 2018;29(1):18–24.
47. Zeevi D, Korem T, Zmora N, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163(5):1079–1094.
48. Berry SE, Valdes AM, Drew DA, et al. Human postprandial responses to food and precision nutrition. Nat Med. 2020;26(6):964–973.
49. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18:83.
50. Karczewski KJ, Snyder MP. Integrative omics for health and disease. Nat Rev Genet. 2018;19(5):299–310.
51. Corral-Acero J, Margara F, Marciniak M, et al. The 'Digital Twin' to enable precision cardiology. Nat Rev Cardiol. 2020;17(12):789–804.
52. Topol EJ. High-performance medicine: convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56.
53. Rothschild D, Weissbrod O, Barkan E, et al. Environment dominates over host genetics in shaping gut microbiota. Nature. 2018;555(7695):210–215.
54. Sanna S, van Zuydam NR, Mahajan A, et al. Causal relationships among gut microbiome, SCFAs and metabolic diseases. Nat Genet. 2019;51(4):600–605.
55. Sinha R, Abu-Ali G, Vogtmann E, et al. Assessment of variation in microbial community amplicon sequencing. Nat Biotechnol. 2017;35(11):1077–1086.

https://doi.org/10.36282/IJASRM/10.03.2025.1961

ISSN 2455-6378

56. Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65(2):330–339.
57. Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67(9):1716–1725.
58. Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:102590.
59. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55–71.
60. Derrien M, Alvarez AS, de Vos WM. The gut microbiota in the first decade of the 21st century. Trends Microbiol. 2019;27(12):997–101

https://doi.org/10.36282/IJASRM/10.03.2025.1961